Drug Industry: Industry and Policies

drug industry: Certain factions in the Democratic Party have no affection for the branded drug industry, and these factions, and their policies, could be tremendously damaging to the industry if their pharmaceutical policies were put into place, the report said, according to Market Watch. However, these policies have always been fiercely opposed by Republicans, and even more moderate proposals...have been successfully fought by the industry, largely through Republican lawmakers. A biotech selloff since the tape early-October release has cost investors $50 billion and caused them obvious concern about the double whammy of both a Democrat president and Democrat-controlled Congress, according to a new report by Leerink Partners. Speculation about the so-called down-ballot effects of Trump nomination has abounded for much of the year. Read more:The market in a minute: Playing a Clinton win with a split Congress While investors saw a Hillary Clinton presidency and a Republican-controlled House of Representatives as an 'OK' election result — one they were comfortable enough with — the odds of another outcome, even if not particularly high, remains materially elevated compared to early in October, the report said. But the tide of public opinion changed with the Trump tape Oct. 7 release, the report said, sending his odds of success plummeting from 35% to about 10% to 15% after their release, and menacing down-ballot Republican prospects too. (news.financializer.com). As reported in the news.